Page last updated: 2024-08-21

oxazoles and Dyslipidemia

oxazoles has been researched along with Dyslipidemia in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dong, T; Fukunaga, K; Ibata, T; Imachi, H; Iwama, H; Kobayashi, T; Lyu, J; Murao, K; Sato, S; Yonezaki, K; Yoshimoto, T; Zhang, G1
Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D1
Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D1
Falk, E; Glien, M; Glombik, H; Herling, AW; Korn, M; Linz, W; Rütten, H; Schäfer, HL; Wendler, W1
Wilding, JP1
Cox, SL1
Braileanu, GT; Ding, SY; Hansen, BC; Ito, K; Tigno, XT1
Bouillot, A; Boullay, AB; Coste, H; Dodic, N; Donche, F; Fouchet, MH; Issandou, M; Junot, C; Magny, SD; Martin, C; Potvain, F; Walker, M1

Reviews

2 review(s) available for oxazoles and Dyslipidemia

ArticleYear
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:11

    Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome

2012
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
    Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:9

    Topics: Adult; Aged; Animals; Area Under Curve; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycated Hemoglobin; Glycine; Half-Life; Humans; Hypoglycemic Agents; Male; Oxazoles; Peroxisome Proliferator-Activated Receptors; Tissue Distribution

2005

Trials

1 trial(s) available for oxazoles and Dyslipidemia

ArticleYear
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    BMC nephrology, 2014, Nov-18, Volume: 15

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Renal Insufficiency, Chronic; Therapeutic Equivalency; Thiazolidinediones; Thiophenes

2014

Other Studies

5 other study(ies) available for oxazoles and Dyslipidemia

ArticleYear
Selective peroxisome proliferator-activated receptor-α modulator K-877 regulates the expression of ATP-binding cassette transporter A1 in pancreatic beta cells.
    European journal of pharmacology, 2018, Nov-05, Volume: 838

    Topics: Animals; ATP Binding Cassette Transporter 1; Benzoxazoles; Butyrates; Cell Line, Tumor; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Glucose; Glucose Intolerance; Humans; Hypolipidemic Agents; Insulin; Insulin-Secreting Cells; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Oxazoles; PPAR alpha; Promoter Regions, Genetic; Rats; RNA, Messenger; Tyrosine

2018
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
    Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9

    Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes

2009
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
    Acta pharmacologica Sinica, 2012, Volume: 33, Issue:1

    Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Oxazoles; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones

2012
A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
    Metabolism: clinical and experimental, 2007, Volume: 56, Issue:10

    Topics: Animals; Apolipoproteins; Blood Glucose; Body Weight; Butyrates; Cholesterol, HDL; Dyslipidemias; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver Function Tests; Macaca mulatta; Male; Oxazoles; PPAR alpha; PPAR gamma; Prediabetic State; Treatment Outcome

2007
Design and evaluation of a novel series of 2,3-oxidosqualene cyclase inhibitors with low systemic exposure, relationship between pharmacokinetic properties and ocular toxicity.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Anticholesteremic Agents; Cataract; Cell Line, Tumor; Dyslipidemias; Enzyme Inhibitors; Eye; Female; Humans; Intramolecular Transferases; Liver; Male; Oxazoles; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley

2008